Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
NCT04057898
Site status not listed — check the official record
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- MN-166, placebo
- Drug
- Lead sponsor
- MediciNova
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 10
- States / cities
- Orange, California • Jacksonville, Florida • Augusta, Georgia + 7 more